Ownership history in Prosight Management, LP Β· 7 quarters on record
This page tracks every 13F SEC filing in which Prosight Management, LP reported a position in CORBUS PHARMACEUTICALS HLDGS (CRBP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Prosight Management, LP underperformed the S&P 500 by β32.0% annually on this CRBP position. Timing score: 60% (3/5 decisions correct). Average cost basis: $8.15. Maximum drawdown during holding period: β74.3%.
β Significantly underperformed the S&P 500 by 32.0% ann.
5 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
3 of 5 add/trim decisions correct
Best entry: $5.31 (2025 Q1) Β· Worst: $20.63 (2024 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
6 adds Β· 1 trim. Bought during 3 of 3 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 1.15% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size